CORTEVA, INC.
SUPPLEMENTAL FINANCIAL DATA AND NON-GAAP RECONCILIATIONS
(UNAUDITED)
January 1, 2018 - December 31, 2025

Corteva Unaudited Pro Forma Information: In order to provide the most meaningful comparison of results of operations, supplemental unaudited pro forma financial information for the first quarter of 2019 and prior has been included in these schedules. These schedules present the pro forma results of Corteva, Inc. ("Corteva" or the "Company"), after giving effect to events that are (1) directly attributable to the merger of DuPont and Dow, debt retirement transactions related to paying off or retiring portions of EIDP's existing debt liabilities, and the separation and distribution to DowDuPont stockholders of all the outstanding shares of Corteva common stock; (2) factually supportable and (3) with respect to the pro forma statements of operations, expected to have a continuing impact on the consolidated results. All periods before, and including, the first quarter of 2019 give effect to the above noted transactions in addition to the common control business combination with DAS, as if it had been consummated on January 1, 2017. Refer to Corteva's Form 10 registration statement filed on May 6, 2019, which can be found on the investors section of the Corteva website, for further details on the above transactions. The pro forma financial statements were prepared in accordance with Article 11 of Regulation S-X that was in effect prior to recent amendments, and are presented for informational purposes only, and do not purport to represent what the results of operations would have been had the above actually occurred on the dates indicated, nor do they purport to project the results of operations for any future period or as of any future date. Refer to Corteva's 8-K filed on August 1, 2019, which can be found on the investors section of the Corteva website, for more information on the Article 11 pro forma financial statements.

Non-GAAP Financial Measures: This presentation includes information that does not conform to U.S. Generally Accepted Accounting Principles ("GAAP") and are considered non-GAAP measures. These measures include operating EBITDA and operating EBITDA margin. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided on pages 2 and 3.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures, except for Free Cash Flow, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the company's control, such as significant items, without unreasonable effort. For significant items reported in the periods presented, refer to the significant items details included within. Beginning January 1, 2020, the company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the noncash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. Due to the ramp-up of Enlist E3™, Corteva significantly reduced the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter. The Company committed to restructuring activities to optimize the Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2028. The Company expects to record approximately $140 million to $150 million net pre-tax restructuring charges during 2026 for these activities.

Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, environmental remediation and legal costs associated with legacy businesses and sites and the 2021 officer indemnification payment. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the company as pre-tax income or expense. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility.

SIGNIFICANT ITEMS (UNAUDITED)
(dollars in millions)

SIGNIFICANT ITEMS	Year 2025 As Reported	Year 2024 As Reported	Year 2023 As Reported	Year 2022 As Reported	Year 2021 As Reported	Year 2020 As Reported	Year 2019 Pro Forma	Year 2018 Pro Forma
Restructuring and asset related charges - net	$ (146)	$ (288)	$ (336)	$ (363)	$ (289)	$ (335)	$ (222)	$ (694)
Employee Retention Credit [1]	—	—	3	9	60	—	—	—
Bayer resolution [1] [3]	(610)	—	—	—	—	—	—	—
Estimated settlement expense [1] [5]	—	(101)	(204)	(87)	—	—	—	—
Inventory write-offs [2] [6]	—	2	(7)	(33)	—	—	—	—
Spare parts write-offs [2] [7]	—	—	(12)	—	—	—	—	—
Settlement costs associated with Russia Exit [1] [6]	—	—	—	(8)	—	—	—	—
Gain (loss) on sale of business, assets and equity investments [1] [6] [7]	37	7	14	10	—	(53)	(24)	22
AltEn facility remediation charge [2] [9]	(37)	—	(10)	(33)	—	—	—	—
Seed sale associated with Russia Exit [6] [8]	—	—	18	3	—	—	—	—
Acquisition-related costs [10]	—	(6)	(45)	—	—	—	—	—
Insurance proceeds[11]	98	71	—	—	—	—	—	—
Loss on deconsolidation of subsidiary [1]	—	—	—	—	—	—	—	(53)
Integration and separation costs [4]	—	—	—	—	—	—	(632)	(571)
Equity securities mark-to-market gain [1]	—	—	—	—	47	—	—	—
Income tax related items [12]	—	—	—	—	—	—	—	(50)
Amortization of inventory step up [2]	—	—	—	—	—	—	(67)	—
Argentina currency devaluation [1]	—	—	—	—	—	—	(33)	—
Loss on early extinguishment of debt	—	—	—	—	—	—	(13)	—
Contract termination [1]	—	—	—	—	(54)	—	—	—
TOTAL PRE-TAX SIGNIFICANT ITEMS BENEFIT (CHARGE) [15]	$ (658)	$ (315)	$ (579)	$ (502)	$ (236)	$ (388)	$ (991)	$ (1,346)
+Total tax (provision) benefit impact of significant items [13]	153	80	131	102	51	86	135	239
+Tax only significant item benefit (charge) [14]	(77)	(116)	45	133	9	192	72	(347)
TOTAL SIGNIFICANT ITEMS BENEFIT (CHARGE), AFTER TAX [16]	$ (582)	$ (351)	$ (403)	$ (267)	$ (176)	$ (110)	$ (784)	$ (1,454)

(1) Included in other income (expense) - net.

(2) Included in cost of goods sold.

(3) Consists of a charge relating to the resolution of litigation with Bayer.

(4) Included in integration and separation costs. Beginning in Q2 2019, this includes both integration and separation costs.

(5) Includes a charge for estimated Lorsban® related charges.

(6) The gain (loss) on sale of business, assets and equity investments recognized in the second quarter 2025, as well as in 2024, 2023 and 2022, are associated with activities related to the 2022 Restructuring Actions. The inventory write-offs, settlement costs associated with Russia Exit and seed sale associated with Russia exit recognized in 2023 and 2022 are also associated with activities related to the 2022 Restructuring Actions. The second quarter 2024 includes a $2 benefit associated with sales of inventory previously reserved for in association with the 2022 Restructuring Actions.

(7) The gain (loss) on sale of business, assets and equity investments recognized in the fourth quarter 2025 and the spare parts write-offs recognized in 2023 are associated with activities related to the Crop Protection Operations Strategy Restructuring Program.

(8) The amounts in 2023 and 2022 include a benefit (charge) of $18 and $3, respectively, relating to the sale of seeds already under production in Russia when the decision to exit the country was made and that the Company was contractually required to purchase. The amounts in 2023 and 2022 consisted of $71 and $8, respectively, of net sales and $53 and $5, respectively, of cost of goods sold.

(9) This charge relates to the increase in the remediation accrual at the AltEn facility relating to Corteva's estimated voluntary contribution to the solid waste and wastewater remedial action plans.

(10) This charge relates to transaction and third-party integration costs associated with the completed acquisitions of Stoller and Symborg as well as the recognition of the inventory fair value step-up, which is included in selling, general and administrative expenses and cost of goods sold, respectively.

(11) Includes proceeds received related to prior significant items.

(12) Relates to a foreign exchange loss related to adjustments to Historical DuPont's foreign currency exchange contracts as a result of U.S. tax reform, included in other income (expense) - net.

(13) The income tax effect for each significant item was calculated based on the statutory tax rate for the jurisdiction(s) in which the significant item was taxable or deductible.

(14) Primarily related to a deferred tax benefit associated with a change in a legal entity's U.S. tax characterization, the establishment of a tax valuation allowance against the individual net deferred tax asset positions of the Brazil Seed legal entity and Brazil Crop Protection legal entity, the impact of deferred taxes and a tax currency change for legal entities within Switzerland, adjustments due to intellectual property realignment, a worthless stock deduction in the U.S., a change in a U.S. legal entity's tax characterization resulting in the establishment of deferred taxes, the release of a tax valuation allowance recorded against the net deferred tax asset position of a Brazil legal entity, changes in valuation allowances recorded against the net deferred tax asset positions of two legal entities in Brazil, U.S. and Swiss Tax Reform, the Internal Reorganizations and Business Separations, the release of a tax valuation allowance recorded against the net deferred tax asset position of a Swiss legal entity, and the establishment of a state tax valuation allowance in the U.S.

(15) Impact on income (loss) from continuing operations before income taxes.

(16) Impact on income (loss) from continuing operations after income taxes.

RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)
(dollars in millions)

RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS AFTER INCOME TAXES TO OPERATING EBITDA	Year 2025 *As Reported*	Year 2024 *As Reported*	Year 2023 *As Reported*	Year 2022 *As Reported*	Year 2021 *As Reported*	Year 2020 *As Reported*	Year 2019 *Pro Forma*	Year 2018 *Pro Forma*
Income (loss) from continuing operations after income taxes (GAAP)	$ 1,204	$ 863	$ 941	$ 1,216	$ 1,822	$ 756	$ 26	$ (4,937)
Provision for (benefit from) income taxes on continuing operations	484	412	152	210	524	(81)	1	395
Income (loss) from continuing operations before income taxes (GAAP)	$ 1,688	$ 1,275	$ 1,093	$ 1,426	$ 2,346	$ 675	$ 27	$ (4,542)
Depreciation and amortization	1,203	1,227	1,211	1,223	1,243	1,177	1,000	909
Interest income	(136)	(132)	(283)	(124)	(77)	(56)	(59)	(86)
Interest expense	180	233	233	79	30	45	91	76
Exchange (gains) losses - net	181	284	397	229	54	174	66	77
Non-operating (benefits) costs - net	39	174	151	(111)	(1,256)	(316)	(129)	(211)
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges (1)	—	—	—	—	—			
Goodwill impairment charge	—	—	—	—	—	—	—	4,503
Significant items (benefit) charge	658	315	579	502	236	388	991	1,346
Separation costs	35	—	—	—	—	—	—	—
Operating EBITDA (Non-GAAP)	$ 3,848	$ 3,376	$ 3,381	$ 3,224	$ 2,576	$ 2,087	$ 1,987	$ 2,072

(1) Effective January 1, 2021, on a prospective basis, the company excludes net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting.

OPERATING EBITDA MARGIN	Year 2025 *As Reported*	Year 2024 *As Reported*	Year 2023 *As Reported*	Year 2022 *As Reported*	Year 2021 *As Reported*	Year 2020 *As Reported*	Year 2019 *Pro Forma*	Year 2018 *As Reported*
Consolidated Net Sales	$ 17,401	$ 16,908	$ 17,226	$ 17,455	$ 15,655	$ 14,217	$ 13,846	$ 14,287
Operating EBITDA (Non-GAAP) (2)	$ 3,848	$ 3,376	$ 3,381	$ 3,224	$ 2,576	$ 2,087	$ 1,987	$ 2,072
Operating EBITDA Margin (Non-GAAP)	22.1 %	20.0 %	19.6 %	18.5 %	16.5 %	14.7 %	14.4 %	14.5 %

(2) See Reconciliation of Non-GAAP Measures above.